Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Diabetic Retinopathy

Clinical Trial Details

Overview

Research Study Summary

A clinical trial seeking patients for a research study for the treatment of Diabetic Macular Edema., Non-proliferative Diabetic Retinopathy or Proliferative Diabetic Retinopathy

Research Study Title

Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema.

Purpose

The purpose of this study is to test the efficacy of an 0.7 mg intravitreal dexamethasone implant (Ozurdex®) on macular leakage and visual acuity for patients with recalcitrant diabetic macular edema.

To Learn more
Phase

2

Gender

Both Male and Female

Age

18 and up

Overall Status

Recruiting

Lead Sponsor

Retina Macula Institute

Duration

14 Months

Facility Type

N/A

Eligibility

Both Male and Female ages 18 Years and up

Inclusion Criteria:

  • Presence of NPDR or PDR as confirmed by fluorescein angiography

  • Prior treatment with > = 2 intravitreal anti-VEGF injections but no treatment in last 4 weeks

  • < 0.1 LogOCT decrease in macular edema on high resolution OCT between initial visit and following treatment with > = 2 intravitreal anti-VEGF injections

  • Age 18 years or older

  • ETDRS Visual acuity between 3 and 78 letters (approximate Snellen equivalent of 20/25 to 20/800)

  • Ability to provide written informed consent

  • Capable of complying with study protocol.

Exclusion Criteria:

  • Intraocular injection of steroid medication within prior 3 months

  • Evidence of significant geographic atrophy on fluorescein angiography in the opinion of the treating physician

  • Concurrent ocular disease (wet AMD, significant ERM, etc) that would limit visual acuity in the opinion of the treating physician

  • Prior vitrectomy surgery

  • Use of systemic steroids (eg, oral, intravenous, intramuscular, epidural, rectal, or extensive dermal) within 1 month prior to day 1.

  • Known history of IOP elevation in response to steroid treatment in either eye that resulted in any of the following: a) = 10 mm Hg increase in IOP in response to steroid injection, or b) IOP = 25 mm Hg and required 2 or more anti-glaucoma medications to keep IOP below 21 mm Hg.

  • Patients who are pregnant.

  • Unwilling or unable to follow or comply with all study related procedures

Site Locations (1)

Country State City Zip Facility and Contact
United States California Torrance 90503 Retina Macula Institute
Gina Kim, B.S
310-944-9393
gina.kim@retinamaculainstitute.com

Ron P Gallemore, M.D, Ph.D
Principal Investigator

Mehran Taban, M.D
Sub-Investigator

Ray Oyakawa, M.D
Sub-Investigator

Behnam Sharareh, B.S
Sub-Investigator

Contact

Gina Kim, B.S
310-944-9393
E-mail:

NCT ID: NCT01571232

Date Last Changed: January 13, 2013

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Some study summaries have been edited for clarity purposes to make them easier to understand. View more study details here.